Prasugrel (Efient): new antiplatelet to prevent atherothrombosis

Prasugrel (Efient) is a new antiplatelet agent to prevent atherothrombotic events in patients with acute coronary syndrome or STEMI under‐ going percutaneous coronary intervention. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Drs Nadra and Redwood consider its potential place in treatment. Copyright © 2010 Wiley Interface Ltd